Simplifying Progress

This is Sartorius

Company Presentation | February 2023

Partner of Life Science Research and the Biopharmaceutical Industry

Our mission

We empower scientists and engineers to simplify and accelerate progress in life science and bioprocessing, enabling the development of new and better therapies and more affordable medicine.

Our vision

We are a magnet and dynamic platform for pioneers and leading experts in our field. We bring creative minds together for a common goal: technological breakthroughs that lead to better health for more people.

Sartorius in Brief

60+
Locations worldwide,
headquartered in Göttingen, Germany

~16,000
Employees[1]

~€4.175bn
Sales revenue[2]

33.8%
EBITDA margin[2,3]

~€24.1bn
Sartorius AG market capitalization[1];
listed on the DAX and TecDAX



~37%
Sales revenue
Americas

~37%
Sales revenue
EMEA

~26%
Sales revenue
Asia | Pacific

1 As of December 31, 2022, 2 FY 2022, 3 Underlying EBITDA

Strategic Focus on the Biopharma Market



Our Solution: Technologies to Accelerate Drug Discovery and Development

Molecule development → **Cell line development**

Identification / validation → Library screening → Lead optimization → Candidate characterization → Gene cloning → Cell line selection → Cell line characterization → Cell banking

Key products

IncuCyte

iQue

Octet

Sartoclear Dynamics

MyCap

Supporting products

Picus NxT

Cubis

Microsart

Centrisart

Octet® BLI System for Antibody Characterization

- ✓ Parallel processing of up to 96 samples; non-destructive and in real-time
- ✓ Quantitation or binding kinetics measured directly in unpurified samples
- ✓ Ease of use with minimal maintenance - perfect for multi-user environments

Octet® Platform Basics

A label-free biomolecule analysis platform based on Biolayer Interferometry (BLI) Technology

- Biomolecules can be analyzed on this platform in their native versions. They do not have to be labeled with any fluorescent markers/tags/dyes.
  - Label-free technologies provide opportunities for probing biomolecular interactions without spatial interference or the auto-fluorescent or quenching effects of labels.

BLI Technology

- Proprietary label-free technology platform that enables both quantitative and kinetic analysis of a biologic molecule
- Ability to detect small molecules ~ 150 Da to ~ 1M Da, large proteins, virus particles and bacterial cells
- Analytical capabilities include protein concentration (c), binding specificity (yes / no), affinity (K_D) and kinetics (k_{on}, k_{off})



Types of Information Generated Using the Octet® Platform

Binding Specificity
Do the molecules interact?



Binding Kinetics:
What is the rate of the interaction?
k_a, k_d



Binding Affinity:
How tightly do the molecules bind?
K_D, K_A
Relative Ranking



Concentration Analysis:
How much analyte is there?

SARTORIUS

The Octet® Technology

Monitoring bio-layer thickness shift (nm-shift) over time







- Optical layer reflects simple white light; second reflection from tip of biosensor, both reach detector
- Analyte binding changes thickness of bio-layer, which is measured at detector



Binding response is measured in real time as a function of increasing biomolecular density on the biosensor surface

Octet® Platform Usage in Antibody and Vaccine Research

Monitor Titer, Vaccine Potency & Stability



Screen & Evaluate Binding Kinetics & Affinities of Antigens in Real-time



Assess Epitope Diversity & Coverage



Identify antibody epitope bins & their relationships

Investigate Virus – Human Receptor Interactions, nAb & Inhibitor Development



Thank you.